Načítá se...
Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells
Clinical trials of imetelstat therapy have indicated that this telomerase inhibitor might have disease-modifying effects in a subset of patients with myelofibrosis (MF). The mechanism by which imetelstat induces such clinical responses has not been clearly elucidated. Using in vitro hematopoietic pr...
Uloženo v:
| Vydáno v: | Blood Adv |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6156882/ https://ncbi.nlm.nih.gov/pubmed/30242099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018022012 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|